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Methods: A retrospective analysis of birth anthropometric data was performed for patients
(nZ 103) with MPS I, II, and VI. Two-tailed t tests were used to compare mean values for body
length and weight at birth between patients with MPS and the general population.
Results: Mean values for birth body length and weight for all studied groups were greater than
in the general population. For body length the differences were statistically significant. When
considered individually, 53% of patients were large for gestational age (LGA) and 30% were
macrosomic. The highest percentage of LGA was observed in MPS II males and MPS VI females
(55% and 56%, respectively), while the highest percentage of macrosomia was observed in MPS
VI males (36%).
Conclusion: At the time of birth, MPS patients were larger than those in the general popula-
tion. High birth weight and/or LGA can be suggestive of MPS disease and should raise suspicion
aiding early disease recognition.
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Table 1 Mean value of body weight and length in the
studied population.
No. Group (n) Body
length (cm)
Body
weight (kg)
1 MPS I (18) 55.6  3.45 3.47  0.61
2 MPS II (56) 55.4  2.68 3.63  0.56
3 MPS VI
Boys (11) 55  3.59 3.82  0.61
Girls (18) 53.8  2.89 3.62  0.56
4 Healthy population
Boys 52.2  2.8 3.50  0.6
Girls 51.3  2.5 3.4  0.5
Data are presented as mean  standard deviation.
MPS Z mucopolysaccharidosis.
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Mucopolysaccharidoses (MPSs) are a group of lysosomal
storage disorders caused by a deficient activity of enzymes
responsible for the catabolism of glycosaminoglycans (GAGs)
leading to a short stature and severe joint and bone disease.1
Mucopolysaccharidosis type I (MPS I) is caused by a deficient
activity of alpha-L-iduronidase (IDUA; EC 3.2.1.76) and is
divided into three subtypes based on the severity of symp-
toms: Hurler syndrome (severe, OMIM 607016), Hurlere-
Scheie syndrome (intermediate, OMIM 607015), and Scheie
syndrome (attenuated, OMIM 607016).1e3 Mucopolysacchar-
idosis type II (MPS II, Hunter disease, OMIM 309900) is an X-
linked recessive disorder caused by a deficient activity of
iduronate-2-sulfatase (IDS, EC 3.1.6.13). Hunter syndrome
affects primarily males while females are nonmanifesting
carriers of Condition 1. Mucopolysaccharidosis type VI (MPS
VI, Maroteaux-Lamy syndrome, MPS VI, OMIM 253200) is
caused by a deficient activity of N-acetylgalactosamine-4-
sulfatase (4-sulfatase, arylsulfatase B, ARSB, EC 3.1.6.12).1,4
Human growth is a multi-factorial and complex process,
involving physiological interplay between nutritional,
endocrine, and metabolic factors, on a wider background of
variation in genetic traits and environmental exposure.5
MPS diseases lead to a profound disruption in normal
mechanisms of growth and development.6 The underlying
cause of degenerative bone and joint disease is a lack of
skeletal remodeling, disordered endochondral and intra-
membranous ossification, disruption of normal elasto-
genesis, and the infiltration by GAGs of the ligaments,
tendons, joint capsules, and other tissue structures.7e9
GAG storage in MPS induces a complex sequence of mo-
lecular abnormalities leading to inflammation, apoptosis
(cartilage), and hyperplasia (synovial membranes), result-
ing in poorly organized and metabolically abnormal con-
nective tissue matrices.7,9e11
In our previous studies, we evaluated and compared
growth patterns in patients with MPS I (n Z 14) and MPS II
(n Z 28).12e14 In this study, which deals exclusively with
birth parameters, additional data as well as MPS VI patients
were added to compare birth body length and weight be-
tween MPS I, II, VI, and the general population.
2. Methods
2.1. Study participants
A retrospective analysis (years 1989e2012) of birth anthro-
pometric data (n Z 103) was performed for patients with
MPS I (18 boys), MPS II (56 boys), and MPS VI (11 boys and 18
girls). All patients with MPS I and II were of Polish origin,
while patients with MPS VI were of Polish (nZ 11), Russian
(nZ 8), Lithuanian (nZ 6), Belarusian (nZ 2), and Estonian
(nZ 2) origin. Birth data were collected from health books
of each patient. All measurements were performed at the
time of birth, in hospitals where the children were born.
All patients were born at term (prematurely born pa-
tients were excluded from the study), and presented
typical clinical features of MPS and had a diagnosis of MPS
type I, II, or VI confirmed by biochemical and molecular
analyses.All patients were naı¨ve to enzyme replacement therapy
(ERT) during the time of the study.
2.2. Study design
The study objectives were to compare mean values for
birth body length and weight between patients with MPS I,
II, VI, and the general population.15
2.3. Anthropometric measurements
Anthropometric measurements were taken according to a
standard technique and included body length/height.
Length was measured in the supine position using a tape
measure. The body weight was measured using an elec-
tronic scale accurate to within 0.05 kg.
2.4. Data analysis
Two-tailed t tests were used to compare mean values for
body length and weight at birth between patients with MPS
I, II, VI, and the general population.
2.5. Ethical consideration
The protocol was approved by the Human-subjects Insti-
tutional Review Board at the Children’s Memorial Health
Institute, Warsaw, Poland. A written informed consent had
to be provided by parents or legal guardians.
3. Results
Mean values for birth body length and weight for all studied
groups were greater than in the general population (Table
1). For body length the differences were statistically sig-
nificant (Figure 1). LGA was defined as a weight, length, or
head circumference that lies above the 90th percentile for
gestational age. Macrosomia, which literally means “big
body,” is defined by the American College of Obstetricians
and Gynecologists, as birth-weight > 4000 g or > 4500 g
irrespective of gestational age. When considered individu-
ally, 53% of patients were large for gestational age (LGA)
and 30% were macrosomic. The highest percentage of LGA
was observed in MPS II males and MPS VI females (55% and
Figure 1 Mean value of birth length comparison with general
population. * Statistically significant, p < 0.01. y Statistically
significant, p Z 0.04. z Statistically significant, p Z 0.01.
MPS Z mucopolysaccharidosis.
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rosomia was observed in MPS VI males (36%). There was no
clear correlation between birth parameters and type of MPS
or severity of the disease.
4. Discussion
In our previous studies, we evaluated and compared growth
patterns in patients with MPS I (n Z 14) and MPS II
(n Z 28).12e14 In this study, which deals exclusively with
birth parameters, additional data as well as MPS VI patients
were added in order to compare birth body length and
weight between MPS I, II, VI, and the general population. In
our cohort, mean values for birth body length and weight
were greater than the general population with values for
birth body length being statistically significant. When
considered individually, 53% of patients were LGA and 30%
were macrosomic. There is a scarcity of literature about
birth measurements of patients with mucopolysacchar-
idoses. In a Brazilian study, the mean birth weight for MPS II
patients with an attenuated or severe form of the disease
was not significantly higher compared with that for Brazil-
ian male newborns.16 However, around 25% of all Brazilian
patients weighed more than the 90th percentile (3.75 kg) at
birth and 7.8% weighed more than 4.3 kg, which is similar to
our results.16 Unfortunately, no length measurements were
provided in this study. The major limitation of our study is
associated with methods used to measure children’s length
at birth. As it is very difficult to measure newborns, birth
measurements may include observational errors. Although
the measuring methods are universal and the same methods
were also used to construct reference charts, they can still
include minor errors when compared with real length.
Macrosomia is associated with numerous perinatal and
maternal complications.17 Increased numbers of high birth
weight infants and LGA have been reported in North America
and Europe.18e20 Increases in maternal anthropometry,
reduced cigarette smoking, and changes in sociodemo-
graphic factors have been suggested to lead to an increase in
the weight of infants born at or after term.19 LGA is an
indication of high prenatal growth rate and is associatedwithseveral risk factors. One of the primary risk factors is poorly
controlled diabetes, particularly gestational diabetes mel-
litus (GDM), as well as preexisting type 2 diabetes mellitus
(DM; Table 2). The risk of macrosomia is directly related to
maternal hyperglycemia (twice as high as in the control
group with glucose levels exceeding 130 mg/dL).21 Apart
from maternal hyperglycemia and fetal hyperinsulinemia,
insulin-like growth factors and selected adipocytokines
produced by adipose tissue and placenta are among the
factors contributing to the development of diabetic fetop-
athy.21 Maternal obesity, weight gain during pregnancy and
maternal hyperlipidemia seem to be other factors involved
in the pathogenesis of feto-maternal complications. It is
important to keep in mind that taller, heavier parents also
tend to have larger babies (familial tall stature). The dif-
ferential diagnosis within LGA includes a group of rare ge-
netic causes such as overgrowth syndromes, which have
significant clinical and molecular overlap and are associated
with developmental delay, tumors, and other anomalies
(Table 2). Congenital overgrowth is defined by a neonatal
weight above the 97th percentile.22 The main differential
diagnoses are Sotos syndrome (OMIM 117550), Weaver syn-
drome (WVS, OMIM 277590), Beckwith-Wiedemann syn-
drome (BWS, OMIM 130650) and Simpson dysmorphia
syndrome (SDYS, Simpson-Golabi-Behmel syndrome, SGBS1,
OMIM 312870).5,23e26 Sotos syndrome is an autosomal domi-
nant overgrowth syndrome with four major diagnostic
criteria: overgrowth with advanced bone age, macro-
cephaly, characteristic facial appearance, and develop-
mental delay.27 It shows considerable phenotypic overlap
with Weaver syndrome (Table 2). BeckwitheWiedemann
syndrome (BWS) is a pediatric overgrowth disorder with an
increased risk of developing embryonic tumor development,
such as Wilms’ tumor and hepatoblastoma. The clinical
presentation is highly variable; some cases lack the hallmark
features of exomphalos (umbilical hernia, abdominal wall
defects), macroglossia, and neonatal gigantism as originally
described by Beckwith28 and Wiedemann et al.29 SGBS is an
X-linked condition characterized, similarly to BWS, by
overgrowth, visceromegaly, and numerous morphological
abnormalities.30 It was initially described as a condition
resulting in a bulldog-like appearance.31 In addition, pa-
tients are at high risk forWilms’ tumor and neuroblastoma.32
The above description of the various overgrowth syndromes
shows that there is no developmental anomaly unique to a
specific syndrome and that the syndromes may involve
overlapping signaling pathways.32 As there exists a wide
spectrum of syndromes, disorders resulting in overgrowth
can represent a diagnostic and therapeutic challenge.25
The majority of MPS children are born after uncompli-
cated pregnancies with normal birth and family history,
with initial signs and symptoms emerging between the ages
of 18 months and 4 years, depending on disease severity.33
The most common presenting feature is a coarsening of
facial features, which becomes apparent between 2 years
and 4 years of age (Table 2, Figure 2).34 Early develop-
mental milestones may also be normal, even in the pres-
ence of significant somatic disease. The neonatal period in
attenuated forms may be normal, while in severe types of
the disease some symptoms might occur early after birth
such as inguinal or umbilical hernias and in the case of MPS
II there is an increased incidence of Mongolian blue spots.35
Table 2 Differential diagnosis between mucopolysaccharidosis types I, II, and VI and other disorders presenting with high birth
weight and/or large for gestational age.
Disease (abbreviation,
OMIM No.)
Manifestations Inheritance/genetic
alterations
Diagnosis Refs
MPS I (OMIM 607016,
OMIM 607015, OMIM
607016)
MPS II (OMIM 309900)
MPS VI (OMIM 253200)
- Facial features (thickening of
the alae nasi, lips, ear lob-
ules, & tongue), plethoric,
rosy-cheeked appearance
- Facial & body hypertrichosis
(scalp hairdcoarse, straight,
& thatch-like hair)
- Umbilical/inguinal hernia
- Some patients fail hearing
screening tests in the 1st y
- Increased incidence of Mon-
golian blue spots (MPS II)
- Specific, pearly, popular skin
eruptions (around the scap-
ulae, trunk, & upper thigh) e
pathognomic for MPS II
- Autosomal recessive
(MPS I, MPS VI)
- X-linked recessive (MPS
II)
- Urine GAG levels
- Enzyme assay
- Mutation analysis
1,13,14
Cerebral gigantism
(Sotos syndrome, SS,
117550)
- Rapid overgrowth with
advanced bone age
- Macrocephaly
- Characteristic facial appear-
ance (high bossed forehead,
sparse frontotemporal hair,
malar flushing, long narrow
face, downslanting palpebral
fissures, prominent narrow
jaw)
- Learning disability (delay of
early developmental mile-
stones, hypotonia, poor co-
ordination, language delay,
intellectual impairment)
developmental delay
- Sporadic in 95% of
cases
- The majority of pa-
tients show a partial
deletion or mutation of
the NSD1 gene encod-
ing nuclear receptor
SET-domain-containing
protein 1 on
chromosome 5q35
- 4 major diagnostic
criteria (overgrowth
with advanced bone
age, macrocephaly,
characteristic facial
appearance, & learning
difficulties)
- Molecular diagnosis is
important (NSD1 muta-
tions & deletions)
5,23e26
Weaver syndrome (WS,
WVS, Marshall-Smith
syndrome, 277590)
- Pre- & post-natal overgrowth
- Advanced osseous (carpal)
maturation
- Characteristic craniofacial
features (micrognathia with a
deep horizontal chin crease)
- Developmental delay
- Autosomal dominant
inheritance has been
reported
- NSD1 mutation
- The molecular basis of
WS is unknown
23,25,26
BeckwitheWiedemann
syndrome (BWS,
130650)
- Increased growth rate during
the latter half of pregnancy &
in the 1st few years of life
(neonatal gigantism)
- Macroglossia
- Increased frequency of mal-
formations (abdominal wall
defects: omphalocele, um-
bilical hernia, diastasis recti;
renal anomalies: renal med-
ullary dysplasia, nephrocalci-
nosis, nephrolithiasis)
- Visceromegaly (liver, spleen,
pancreas, kidneys, adrenals)
- Predisposition to embryonal
malignancies (Wilms tumor &
hepatoblastoma)
- Variable; sporadic in
85% of cases, but can
be autosomal domi-
nant; also can be
caused by uniparental
disomy & imprinting
defects
- The mode of inheri-
tance of BWS is com-
plex. The current
understanding of the
molecular basis of the
syndrome is that aber-
rations in the chromo-
somal region 11p15.5
involving imprinted
genes have a pivotal
- Diagnosis is based on
clinical findings, a
’mild’ presentation
may include prominent
tongue & umbilical
hernia
- Although consensus
diagnostic criteria for
BWS have not been
defined, the presence
of 3 major features
(e.g. prenatal & post-
natal overgrowth,
macroglossia, &
abdominal wall de-
fects) or 2 major fea-
tures & 1 minor feature
5,23e26,32
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Table 2 (continued )
Disease (abbreviation,
OMIM No.)
Manifestations Inheritance/genetic
alterations
Diagnosis Refs
- Hypoglycemiad30e50% of
babiesdpathognomonic
finding: fetal adrenocortical
cytomegaly
- Ear anomalies
role in disease
formation
- Possible patterns
include autosomal
dominant inheritance
with variable expres-
sivity, contiguous gene
duplication at 11p15, &
genomic imprinting
resulting from a defec-
tive or absent copy of
the maternally derived
gene
(e.g., ear anomalies,
neonatal hypoglyce-
mia, nephromegaly, &
hemihyperplasia) is
required for the post-
natal clinical diagnosis
of BWS
- A careful cytogenetic
analysis of the 11p15
region is recommended
- Prenatal diagnosis by
ultrasonography is
possible
- Molecular diagnosis is
important to confirm
the provisional BWS
clinical diagnosis & to
identify BWS patients
with cancer
susceptibility
Simpson-Golabi-Behmel
syndrome, Simpson
dysmorphia syndrome
(SGBS, SDYS, 312870)
- Pre- & postnatal overgrowth
- Coarse facies
- Congenital heart defects
- Other congenital abnormal-
ities (dysplastic kidneys,
vertebral & rib defects,
postaxial hexadactyly, super-
numerary nipples)
- High risk for Wilms tumor &
neuroblastoma
- X-linked recessive
- Defects involving the
GPC3 (glypican 3)
gene, located on Xq26,
which encodes an
extracellular proteo-
glycan believed to
function in growth
regulation
- Diagnosis is based on
clinical findings, a
family history consis-
tence with X-linked in-
heritance, & the
results of molecular
genetic testing of GPC3
5,23e26
Perlman syndrome - Fetal overgrowth & neonatal
macrosomia
- Polyhydramnios
- Visceromegaly
- Nephromegaly
- Predisposition (bilateral) for
Wilms’ tumor
- Macrocephaly, dysmorphic
facial features (micrognathia,
round face, broad flat nasal
bridge)
- Mental retardation
- Autosomal recessive - The molecular basis of
Perlman is unknown
23e26
BWSZ BeckwitheWiedemann Syndrome; GAG Z glycosaminoglycan; GPC3 Z glypican 3; MPS Z mucopolysaccharidosis;
NSD1 Z nuclear receptor SET-domain-containing protein 1; OMIMZOnline Mendelian Inheritance in Man; WSZWeaver syndrome.
Can Macrosomia or LGA Be Predictive of MPS? 185The age of diagnosis is usually between 9 months and 36
months, but may be significantly delayed in attenuated
forms.36e38 Including MPS disease in the diagnostic algo-
rithm of LGA and macrosomia may increase the chances of
diagnosing these patients very early in life, which is crucial
for efficient treatment.39
The pathomechanism of the prenatal and early postnatal
overgrowth in MPS disease remains unclear. Linear growth
during childhood occurs primarily from chondrocyte dif-
ferentiation and replication at the growth plate in the
distal epiphyseal and central metaphyseal regions of long
bones. Childhood growth is stimulated by human growthhormone (hGH), which is secreted in a pulsatile manner
from the anterior pituitary, primarily under the control of
hypothalamic growth hormone releasing hormone.25 hGH
influences linear growth by acting on the growth plate
directly, as well as through insulin-like growth factor (IGF)
I, which is secreted from liver upon hGH stimulation. IGF-I
circulates bound to IGF-binding protein (IGFBP) 3 in a
ternary complex, the critical integrity of which is main-
tained by an acid/labile subunit (ALS). Insulin and insulin-
like signaling regulate systemic nutrient sensing and IGF-I
is a critical determinant of growth in childhood, while
IGF-II plays a more influential role prenatally.40 Thyroid
Figure 2 Birth photos of two patients with mucopolysaccharidosis type II.
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growth plate.25 In MPS I, II, and VI accumulating GAGs are
heparan sulfate (HS, in MPS I and II) and dermatan sulfate
(DS, in MPS I, II, and VI). HS is one of the most prevalent
types of GAGs found on the cell surface and is not a unique
structure but a collection of related molecules with
different patterns of sulfation as well as other modifica-
tions. These structural variants are found in tissue-specific
distributions and show age- and disease-related changes.
HS is a negatively charged molecule that binds to a variety
of extracellular proteins, including growth factors and HS-
modified proteoglycans (HSPGs) serving as growth-factor
coreceptors, which affect the delivery or assembly of li-
gands into signaling complexes. Bishop et al speculates that
the over-growth in fetal and early postnatal life could be
connected to the fact that HS, acting as a coreceptor, binds
to several proteins, including growth factors. An increased
level of HS might therefore overstimulate axial bone growth
in children with MPS at early developmental stages. Hinek
and Wilson7 showed that the process of elastogenesis took
place in the shaft of long bones during fetal life and ac-
cumulations of DS lead to early disruption of normal elas-
togenesis. Their data suggested that dermatan sulfate-
bearing moieties bind to and cause functional inactivation
of the 67-kDa elastin-binding protein, a molecular chap-
erone for tropoelastin, which normally facilitates its
secretion and assembly into elastic fibers.7 Additionally,
lysosomal GAG accumulation has been documented in the
pituitary and thyroid gland of MPS II children.165. Conclusion
At the time of birth, many MPS patients are larger than the
general population. High birth weight and/or LGA can be
suggestive of MPS disease and should raise suspicion aiding
in early disease recognition.Conflicts of interest
A.J. is currently a full-time employee of Shire Pharmaceu-
ticals, however she did not have any conflict of interest atthe time of the study or at the time of preparation of the
manuscript. The other authors declare no conflicts of
interest.Acknowledgments
The authors would like to thank Professor Zakharova and
Professor Voskoboeva (Research Center for Medical Ge-
netics, Moscow, Russian Federation), Professor Cimbalis-
tiene (Vilnius University Hospital, Santariskiu Klinikos,
Vilnius, Lithuania), Professor Gusina and Dr Kulpanovich
(National Medical Center “Mother and Child”, Minsk,
Belarus), and Professor Katrin O˜unap (Department of Pe-
diatrics, University of Tartu, Tartu, Estonia) for providing
the data about their patients. The authors would also like
to thank Dr Marucha (The Children’s Memorial Health
Institute, Warsaw, Poland) for her support with data
collection.References
1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Valle
D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Bal-
labio A, et al., editors. The online metabolic and molecular
basis of inherited disease. New York: McGraw-Hill.
2. Roubicek M, Gehler J, Spranger J. The clinical spectrum of
alpha-L-iduronidase deficiency. Am J Med Genet 1985;20:
471e81.
3. Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM,
Muenzer J, et al. Long-term efficacy and safety of laronidase in
the treatment of mucopolysaccharidosis I. Pediatrics 2009;
123:229e40.
4. Opoka-Winiarska V, Jurecka A, Emeryk A, Tylki-Szymanska A.
Osteoimmunology in mucopolysaccharidoses type I, II, VI and
VII. Immunological regulation of the osteoarticular system in
the course of metabolic inflammation. Osteoarthritis Cartilage
2013;21:1813e23.
5. Sabin MA, Werther GA, Kiess W. Genetics of obesity and over-
growth syndromes. Best Pract Res Clin Endocrinol Metab 2011;
25:207e20.
6. Oussoren E, Brands MM, Ruijter GJ, der Ploeg AT, Reuser AJ.
Bone, joint and tooth development in mucopolysaccharidoses:
Can Macrosomia or LGA Be Predictive of MPS? 187relevance to therapeutic options. Biochim Biophys Acta 2011;
1812:1542e56.
7. Hinek A, Wilson SE. Impaired elastogenesis in Hurler disease:
dermatan sulfate accumulation linked to deficiency in elastin-
binding protein and elastic fiber assembly. Am J Pathol 2000;
156:925e38.
8. Pastores GM, Meere PA. Musculoskeletal complications associ-
ated with lysosomal storage disorders: Gaucher disease and
Hurler-Scheie syndrome (mucopolysaccharidosis type I). Curr
Opin Rheumatol 2005;17:70e8.
9. Simonaro CM, D’Angelo M, He X, Eliyahu E, Shtraizent N,
Haskins ME, et al. Mechanism of glycosaminoglycan-mediated
bone and joint disease: implications for the mucopoly-
saccharidoses and other connective tissue diseases. Am J
Pathol 2008;172:112e22.
10. Simonaro CM, D’Angelo M, Haskins ME, Schuchman EH. Joint
and bone disease in mucopolysaccharidoses VI and VII: identi-
fication of new therapeutic targets and biomarkers using ani-
mal models. Pediatr Res 2005;57:701e7.
11. Simonaro CM, Haskins ME, Schuchman EH. Articular chon-
drocytes from animals with a dermatan sulfate storage disease
undergo a high rate of apoptosis and release nitric oxide and
inflammatory cytokines: a possible mechanism underlying
degenerative joint disease in the mucopolysaccharidoses. Lab
Invest 2001;81:1319e28.
12. Tylki-Szymanska A, Rozdzynska A, Jurecka A, Marucha J,
Czartoryska B. Anthropometric data of 14 patients with
mucopolysaccharidosis I: retrospective analysis and efficacy of
recombinant human alpha-L-iduronidase (laronidase). Mol
Genet Metab 2010;99:10e7.
13. Rozdzynska A, Tylki-Szymanska A, Jurecka A, Cieslik J. Growth
pattern and growth prediction of body height in children with
mucopolysaccharidosis type II. Acta Paediatr 2011;100:456e60.
14. Ro´ _zd _zynska-Swia˛tkowska A, Jurecka A, Cieslik J, Tylki-
Szymanska A. Growth patterns in children with mucopoly-
saccharidosis I and II. World J Pediatr 2015;11:226e31.
15. Malinowski A. Poznan child: Norms for physical development.
Poznan. 1976.
16. Tomatsu S, Montan˜o AM, Oikawa H, Giugliani R, Harmatz P,
Smith M, et al. Impairment of body growth in mucopoly-
saccharidoses. In: Preedy VR, editor. Handbook of growth and
growth monitoring in health and disease. New York: Springer;
2012. p.2091e117.
17. Ng SK, Olog A, Spinks AB, Cameron CM, Searle J, McClure RJ.
Risk factors and obstetric complications of large for gestational
age births with adjustments for community effects: results
from a new cohort study. BMC Public Health 2010;10:460.
18. Ananth CV, Wen SW. Trends in fetal growth among singleton
gestations in the United States and Canada, 1985 through 1998.
Semin Perinatol 2002;26:260e7.
19. Kramer MS, Morin I, Yang H, Platt RW, Usher R, McNamara H,
et al. Why are babies getting bigger? Temporal trends in fetal
growth and its determinants. J Pediatr 2002;141:538e42.
20. Surkan PJ, Hsieh CC, Johansson AL, Dickman PW, Cnattingius S.
Reasons for increasing trends in large for gestational age
births. Obstet Gynecol 2004;104:720e6.
21. Ehrlich SF, Crites YM, Hedderson MM, Darbinian JA, Ferrara A.
The risk of large for gestational age across increasing cate-
gories of pregnancy glycemia. Am J Obstet Gynecol 2011;204:
240.22. Neri G, Moscarda M. Overgrowth syndromes: a classification.
Endocr Dev 2009;14:53e60.
23. Ekmektzoglou K, Demestiha T, Troupis G, Xanthos T. Com-
monest overgrowth syndromes. Fetal Pediatr Pathol 2012;31:
94e111.
24. Vora N, Bianchi DW. Genetic considerations in the prenatal
diagnosis of overgrowth syndromes. Prenat Diagn 2009;29:
923e9.
25. Neylon OM, Werther GA, Sabin MA. Overgrowth syndromes.
Curr Opin Pediatr 2012;24:505e11.
26. Verge CF, Mowat D. Overgrowth. Arch Dis Child 2010;95:458e63.
27. Cole TR, Hughes HE. Sotos syndrome: a study of the diagnostic
criteria and natural history. J Med Genet 1994;31:20e32.
28. Beckwith JB. Macroglossia, omphalocele, adrenal cytomegaly,
gigantism, and hyperplastic visceromegaly. Birth Defects Orig
Artic Ser 1969;2:188e96.
29. Weksberg R, Shuman C, Beckwith JB. BeckwitheWiedemann
syndrome. Eur J Hum Genet 2010;18:8e14.
30. Xuan JY, Hughes-Benzie RM, MacKenzie AE. A small interstitial
deletion in the GPC3 gene causes SimpsoneGolabieBehmel
syndrome in a Dutch-Canadian family. J Med Genet 1999;36:
57e8.
31. Simpson JL, Landey S, New M, German J. A previously unrec-
ognized X-linked syndrome of dysmorphia. Birth Defects Orig
Artic Ser 1975;11:18e24.
32. Enklaar T, Zabel BU, Prawitt D. BeckwitheWiedemann syn-
drome: multiple molecular mechanisms. Expert Rev Mol Med
2006;8:1e19.
33. Scarpa M, Alma´ssy Z, Beck M, Bodamer O, Bruce IA, De
Meirleir L, et al. Mucopolysaccharidosis type II: European rec-
ommendations for the diagnosis and multidisciplinary man-
agement of a rare disease. Orphanet J Rare Dis 2011;6:72.
34. Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Mun˜oz V, et al.
Recognition and diagnosis of mucopolysaccharidosis II (Hunter
syndrome). Pediatrics 2008;121:e377e86.
35. Sapadin AN, Friedman IS. Extensive Mongolian spots associated
with Hunter syndrome. J Am Acad Dermatol 1998;39:1013e5.
36. Jurecka A, Zakharova E, Malinova V, Voskoboeva E, Tylki-
Szymanska A. Attenuated osteoarticular phenotype of type VI
mucopolysaccharidosis: a report of four patients and a review
of the literature. Clin Rheumatol 2014;33:725e31.
37. Jurecka A, Zakharova E, Cimbalistiene L, Gusina N,
Kulpanovich A, Golda A, et al. Mucopolysaccharidosis type VI: a
predominantly cardiac phenotype associated with a homozy-
gosity for p.R152W mutation in the ARSB gene. Am J Med Genet
A 2013;161A:1291e9.
38. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L,
Guffon N, et al. Mucopolysaccharidosis type II (Hunter syn-
drome): a clinical review and recommendations for treatment
in the era of enzyme replacement therapy. Eur J Pediatr 2008;
167:267e77.
39. Tylki-Szymanska A, Jurecka A, Zuber Z, Rozdzynska A,
Marucha J, Czartoryska B. Enzyme replacement therapy for
mucopolysaccharidosis II from 3 months of age: 3-year follow-
up. Acta Paediatr 2012;101:e42e7.
40. Rikken B, van Doorn J, Ringeling A, Van den Brande JL,
Massa G, Wit JM. Plasma levels of insulin-like growth factor
(IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of
childhood growth hormone deficiency. Horm Res 1998;50:
166e76.
